Tobira Therapeutics Overview

  • Founded
  • 2006
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 20
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $1.67B
Latest Deal Amount
  • Investors
  • 1

Tobira Therapeutics General Information

Description

Developer of antiviral compounds for treating human immunodeficiency virus (HIV) infection. The company develops TBR-652 and TBR-220 antagonists for the treatment of HIV or AIDS, hepatitis and related infectious conditions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
Primary Office
  • 701 Gateway Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tobira Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 01-Nov-2016 $1.67B 000.00 00.000 Completed Generating Revenue
7. Reverse Merger 05-May-2015 000.00 Completed Clinical Trials - Phase 3
6. IPO 05-May-2015 0000 00000 Cancelled Clinical Trials - Phase 3
5. Convertible Debt 09-Mar-2015 0000 000.00 Completed Clinical Trials - Phase 3
4. Debt - General 30-Jun-2014 0000 000.00 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series B) 30-Jul-2012 0000 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 29-Sep-2010 $21.2M $52.2M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Aug-2007 $31M $31M 000.00 Completed Product Development
To view Tobira Therapeutics’s complete valuation and funding history, request access »

Tobira Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Tobira Therapeutics’s complete cap table history, request access »

Tobira Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antiviral compounds for treating human immunodeficiency virus (HIV) infection. The company develops TBR-652
Pharmaceuticals
South San Francisco, CA
20 As of 2016
000.00
0.000 0000-00-00
000000&0 000.00

00000000

t esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt
0000 000000000
New York, NY
000 As of 0000
00000
000000 - 000 00000

00000000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
South San Francisco, CA
00000 As of 0000
000.00
0000 0000-00-00
00000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tobira Therapeutics Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intercept(Biotechnology) Formerly VC-backed New York, NY 000 00000 000000 - 000 00000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
000000 Formerly VC-backed Austin, TX 00 00000 000000000 00000
00000000 000000000 Corporation West Conshohocken, PA 00 000.00 000000 - 000 000.00
0000 000000000000 Formerly VC-backed Newton, MA 00 0000 000000000 - 0000
You’re viewing 5 of 15 competitors. Get the full list »

Tobira Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Martine Kraus Ph.D Vice President, Regulatory Affairs
Mark Menning Ph.D Director of Pharmaceutical Sciences
Eric Lefebvre MD Chief Medical Officer
You’re viewing 3 of 11 executive team members. Get the full list »

Tobira Therapeutics Board Members (11)

Name Representing Role Since
Carol Brosgart MD Self Board Member 000 0000
Graeme Moyle MD Self Board Member 000 0000
Gwen Melincoff Self Board Member 000 0000
Jeffrey Cooper Self Board Member 000 0000
You’re viewing 4 of 11 board members. Get the full list »

Tobira Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tobira Therapeutics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abingworth Management Venture Capital Minority 000 0000 000000 0
Andera Partners PE/Buyout Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
Canaan Partners Venture Capital Minority 000 0000 000000 0
Domain Associates Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Tobira Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 05-May-2015 000000000000000000 Biotechnology
To view Tobira Therapeutics’s complete acquisitions history, request access »